Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Gender Health Policy topic
No spam. Unsubscribe anytime.
Heated, multi‑hour Judiciary hearing on LB 731: sponsor seeks extended malpractice window and detransition coverage; medical community warns of chilling effect
Summary
Kathleen Kautz’s LB 731 would extend malpractice filing windows tied to gender‑affirming care, create a private cause of action, and require insurers that covered transition to pay for detransition/reconstruction; proponents described individual harms and gaps in coverage while medical groups, nurses, insurers and civil‑rights organizations warned the bill would increase liability, raise costs, deter providers and reduce access.
Kathleen Kautz opened an annotated hearing on LB 731 by saying the bill addresses people who have undergone medical gender‑affirming procedures and later seek redress or reconstruction. In extended introductory testimony she described three strands of the bill: extending filing windows for claims tied to gender‑altering procedures, creating a private right of action and requiring insurers that previously covered transition care also to provide certain detransition or reconstructive services.
“K. B. 7 31 focuses on the needs of those individuals who have engaged in medicalized treatments of their gender dysphoria and who experience regret,” Kautz told the committee (paraphrase from her opening testimony), framing the measure as access and accountability legislation for people who say they were harmed.
Invited proponents included faith groups, detransition support networks and individual witnesses who described long‑term medical complications, difficulty obtaining reconstructive care and obstacles to insurance coverage. Supporters asked for longer statutes of limitations and for required insurer coverage of medically necessary reconstructive and follow‑up procedures.
A broad coalition of medical, nursing and behavioral‑health organizations testified in opposition or neutrality. The Nebraska Medical Association, the Nebraska Nurses Association, the Nebraska Insurance Federation and professional associations warned LB 731 would: extend malpractice exposure far beyond Nebraska’s existing malpractice framework, create a specialized litigation path that could be used to target clinicians, raise malpractice premiums and prompt insurers to exclude gender‑affirming care. Dr. Elizabeth Constance (Nebraska Medical Association) said the bill “abandons established liability principles” and warned that expanding a statute of limitations to as long as 12 years would destabilize provider risk management. Several clinicians, including reproductive endocrinologists and pediatric mental‑health specialists, said the medical evidence supports gender‑affirming care for appropriate patients and that regret rates are small; they warned LB 731 would chill care and reduce access, particularly in rural areas.
Insurance industry testimony (Nebraska Insurance Federation) emphasized mandate costs, potential premium impacts, and uncertainty about which plans the language would affect; federation representatives said they oppose additional coverage mandates they have not vetted for federal/ERISA consequences.
Committee members asked detailed procedural questions about retroactivity, how the new cause of action would interact with existing malpractice law, definitions (for example, what constitutes “gender altering” or “detransition”), and whether proposed insurer obligations would apply only where transition coverage previously existed. Several members pressed sponsors on drafting clarity and on balancing access for potential detransition patients with preserving access for people seeking gender‑affirming care.
No vote or formal action was recorded. The sponsor said she would work with stakeholders on language and indicated plans to refine definitions and exceptions; opponents urged the committee not to advance the bill without major revisions.
PROVENANCE: The hearing began with the annotated introduction at SEG 1222 and continued through extensive invited and public testimony; the committee closed the LB 731 hearing at SEG 6639.
